IR@PKUHSC  > 北京大学药学院  > 药剂学系
学科主题药学
Alzheimer′s disease progression model based on integrated biomarkers and clinical measures
Qiu, Yue1,2; Li, Liang1,2; Zhou, Tian-yan1,2; Lu, Wei1,2; Alzheimer′ s Dis Neuroimaging
关键词Alzheimer&prime s disease mild cognitive impairment A beta(42) p-tau hippocampus ADAS-cog disease progression model NONMEM
刊名ACTA PHARMACOLOGICA SINICA
2014-09-01
DOI10.1038/aps.2014.57
35期:9页:1111-1120
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Chemistry, Multidisciplinary ; Pharmacology & Pharmacy
资助者Alzheimer&prime ; s disease Neuroimaging Initiative (ADNI, National Institutes of Health Grant) ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; Canadian Institutes of Health Research ; NIH ; Dana Foundation ; Alzheimer&prime ; s disease Neuroimaging Initiative (ADNI, National Institutes of Health Grant) ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; Canadian Institutes of Health Research ; NIH ; Dana Foundation
研究领域[WOS]Chemistry ; Pharmacology & Pharmacy
关键词[WOS]COGNITIVE IMPAIRMENT ; IN-VIVO ; NEURODEGENERATION ; THERAPEUTICS ; AUTOPHAGY ; MELATONIN ; DEMENTIA ; ATROPHY ; PLAQUES ; TAU
英文摘要

Aim: Biomarkers and image markers of Alzheimer′s disease (AD), such as cerebrospinal fluid A beta(42) and p-tau, are effective predictors of cognitive decline or dementia. The aim of this study was to integrate these markers with a disease progression model and to identify their abnormal ranges.

Methods: The data of 395 participants, including 86 normal subjects, 108 early mild cognitive impairment (EMCI) subjects, 120 late mild cognitive impairment (LMCI) subjects, and 81 AD subjects were obtained from the Alzheimer′s Disease Neuroimaging Initiative (ADNI) database. For the participants, baseline and long-term data on cerebrospinal fluid A beta(42) and p-tau, hippocampal volume, and ADAS-cog were available. Various linear and nonlinear models were tested to determine the associations among the ratio of A beta(42) to p-tau (the Ratio), hippocampal volume and ADAS-cog.

Results: The most likely models for the Ratio, hippocampal volume, and ADAS-cog (logistic, E-max, and linear models, respectively) were used to construct the final model. Baseline disease state had an impact on all the 3 endpoints (the Ratio, hippocampal volume, and ADAS-cog), while APOE epsilon 4 genotype and age only influence the Ratio and hippocampal volume.

Conclusion: The Ratio can be used to identify the disease stage for an individual, and clinical measures integrated with the Ratio improve the accuracy of mild cognitive impairment (MCI) to AD conversion forecasting.

语种英语
所属项目编号U01 AG024904 ; P30 AG010129 ; K01 AG030514
资助者Alzheimer&prime ; s disease Neuroimaging Initiative (ADNI, National Institutes of Health Grant) ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; Canadian Institutes of Health Research ; NIH ; Dana Foundation ; Alzheimer&prime ; s disease Neuroimaging Initiative (ADNI, National Institutes of Health Grant) ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; Canadian Institutes of Health Research ; NIH ; Dana Foundation
WOS记录号WOS:000341225700002
Citation statistics
Cited Times:4[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62372
Collection北京大学药学院_药剂学系
作者单位1.Peking Univ, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Dept Pharmaceut, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
Recommended Citation
GB/T 7714
Qiu, Yue,Li, Liang,Zhou, Tian-yan,et al. Alzheimer′s disease progression model based on integrated biomarkers and clinical measures[J]. ACTA PHARMACOLOGICA SINICA,2014,35(9):1111-1120.
APA Qiu, Yue,Li, Liang,Zhou, Tian-yan,Lu, Wei,Alzheimer&prime,&s Dis Neuroimaging.(2014).Alzheimer′s disease progression model based on integrated biomarkers and clinical measures.ACTA PHARMACOLOGICA SINICA,35(9),1111-1120.
MLA Qiu, Yue,et al."Alzheimer′s disease progression model based on integrated biomarkers and clinical measures".ACTA PHARMACOLOGICA SINICA 35.9(2014):1111-1120.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Qiu, Yue]'s Articles
[Li, Liang]'s Articles
[Zhou, Tian-yan]'s Articles
百度学术
百度学术Similar articles in
[Qiu, Yue]'s Articles
[Li, Liang]'s Articles
[Zhou, Tian-yan]'s Articles
必应学术
必应学术Similar articles in
[Qiu, Yue]'s Articles
[Li, Liang]'s Articles
[Zhou, Tian-yan]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.